UA97813C2 - Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола - Google Patents

Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола Download PDF

Info

Publication number
UA97813C2
UA97813C2 UAA200904218A UAA200904218A UA97813C2 UA 97813 C2 UA97813 C2 UA 97813C2 UA A200904218 A UAA200904218 A UA A200904218A UA A200904218 A UAA200904218 A UA A200904218A UA 97813 C2 UA97813 C2 UA 97813C2
Authority
UA
Ukraine
Prior art keywords
peg
alpha
beta
castor oil
methoxy
Prior art date
Application number
UAA200904218A
Other languages
English (en)
Ukrainian (uk)
Inventor
Жан Франсуа Александр Лукас Эги
Вим Альберт Алекс Элтерман
Йоланда Лидия Ланг
Сигрид Карл Мария Стокбрукс
Карина Лейс
Ремоортере Петер Йозеф Мария ван
Анна Фор
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37983588&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA97813(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of UA97813C2 publication Critical patent/UA97813C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Abstract

Данное изобретение касается фумаратной соли (альфа S, бета R)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола, фармацевтических композиций, которые содержат как активный ингредиент указанную соль, и способов их получения.
UAA200904218A 2006-12-05 2007-03-12 Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола UA97813C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125443 2006-12-05
PCT/EP2007/063186 WO2008068231A1 (en) 2006-12-05 2007-12-03 Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Publications (1)

Publication Number Publication Date
UA97813C2 true UA97813C2 (ru) 2012-03-26

Family

ID=37983588

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200904218A UA97813C2 (ru) 2006-12-05 2007-03-12 Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола

Country Status (34)

Country Link
US (1) US8546428B2 (ru)
EP (1) EP2086940B1 (ru)
JP (2) JP2010511663A (ru)
KR (1) KR101514700B1 (ru)
CN (2) CN101547904A (ru)
AP (1) AP2498A (ru)
AR (1) AR064149A1 (ru)
AU (1) AU2007328945B2 (ru)
BR (1) BRPI0719693A2 (ru)
CA (1) CA2668512C (ru)
CL (1) CL2007003472A1 (ru)
CY (1) CY1113594T1 (ru)
DK (1) DK2086940T3 (ru)
EA (1) EA017091B9 (ru)
ES (1) ES2387923T3 (ru)
HK (1) HK1214513A1 (ru)
HR (1) HRP20120639T1 (ru)
IL (1) IL199077A (ru)
JO (1) JO2973B1 (ru)
ME (1) ME01456B (ru)
MX (1) MX2009005909A (ru)
MY (1) MY148844A (ru)
NO (1) NO342773B1 (ru)
NZ (1) NZ576485A (ru)
PE (1) PE20081350A1 (ru)
PL (1) PL2086940T3 (ru)
PT (1) PT2086940E (ru)
RS (1) RS52408B (ru)
SI (1) SI2086940T1 (ru)
TW (1) TWI417098B (ru)
UA (1) UA97813C2 (ru)
UY (1) UY30762A1 (ru)
WO (1) WO2008068231A1 (ru)
ZA (1) ZA200903907B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CZ2014708A3 (cs) 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
DK3250182T3 (da) * 2015-01-27 2023-06-26 Janssen Pharmaceutica Nv Dispergible sammensætninger
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
RU2018111482A (ru) * 2015-10-20 2019-11-21 Чжэцзян Хисунь Фармасьютикал Ко., Лтд. Кристаллические формы бедаквилин фумарата и способы их получения
EA037520B1 (ru) * 2016-07-20 2021-04-07 Новартис Аг Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2
CN106316943A (zh) * 2016-07-27 2017-01-11 重庆华邦制药有限公司 富马酸贝达喹啉晶型化合物的精制方法
WO2020144197A1 (en) 2019-01-09 2020-07-16 Janssen Pharmaceutica Nv Combination in the treatment of nontuberculous mycobacterial diseases
WO2020161743A1 (en) * 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
KR102303635B1 (ko) * 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
CN111888477B (zh) * 2020-09-15 2023-03-07 北京福元医药股份有限公司 一种贝达喹啉药物制剂
CN116406270A (zh) 2020-11-12 2023-07-07 詹森药业有限公司 在治疗非结核分枝杆菌疾病时的贝达喹啉、乙胺丁醇和大环内酯的组合
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
JP2001503411A (ja) 1996-10-28 2001-03-13 ディパートメント オブ ジ アーミー，ユー．エス．ガバメント 抗生物質耐性感染症の処置のための化合物、組成物および方法
IL122025A (en) * 1996-10-30 2003-01-12 Lilly Co Eli Use of raloxifene or pharmaceutically acceptable salts or solvates thereof, in the preparation of a medicament for preventing breast cancer
US6819464B2 (en) * 2002-06-19 2004-11-16 Seiko Epson Corporation Optical modulator, optical device and projector
EP1527050B1 (en) * 2002-07-25 2010-04-07 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
SI1753427T1 (sl) * 2004-05-28 2008-10-31 Janssen Pharmaceutica Nv Uporaba substituiranih kinolinskih derivatov za zdravljenje na zdravila odpornih mikobakterijskih bolezni
KR101276571B1 (ko) * 2004-09-02 2013-06-18 얀센 파마슈티카 엔.브이. 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 푸마레이트
BG66437B1 (bg) * 2004-12-24 2014-07-31 Janssen Pharmaceutica N.V. Използване на хинолинови съединения за лечение на латентна туберкулоза

Also Published As

Publication number Publication date
AP2498A (en) 2012-10-19
CA2668512A1 (en) 2008-06-12
AU2007328945A1 (en) 2008-06-12
PL2086940T3 (pl) 2012-10-31
IL199077A (en) 2016-09-29
AU2007328945B2 (en) 2014-04-03
EP2086940B1 (en) 2012-05-16
KR101514700B1 (ko) 2015-04-24
ES2387923T3 (es) 2012-10-04
JO2973B1 (en) 2016-03-15
TW200838527A (en) 2008-10-01
JP2015028049A (ja) 2015-02-12
US8546428B2 (en) 2013-10-01
CL2007003472A1 (es) 2008-08-22
HRP20120639T1 (hr) 2012-08-31
NO342773B1 (no) 2018-08-06
EA017091B1 (ru) 2012-09-28
RS52408B (en) 2013-02-28
MX2009005909A (es) 2009-06-16
EA017091B9 (ru) 2014-10-30
ZA200903907B (en) 2013-08-28
DK2086940T3 (da) 2012-08-20
EP2086940A1 (en) 2009-08-12
CN101547904A (zh) 2009-09-30
UY30762A1 (es) 2008-07-03
PT2086940E (pt) 2012-08-09
TWI417098B (zh) 2013-12-01
JP2010511663A (ja) 2010-04-15
EA200970532A1 (ru) 2009-10-30
SI2086940T1 (sl) 2012-09-28
CY1113594T1 (el) 2016-06-22
ME01456B (me) 2014-04-20
NZ576485A (en) 2012-01-12
HK1214513A1 (zh) 2016-07-29
AP2009004870A0 (en) 2009-06-30
MY148844A (en) 2013-06-14
NO20092535L (no) 2009-08-06
CA2668512C (en) 2015-03-24
KR20090087020A (ko) 2009-08-14
CN105012303A (zh) 2015-11-04
US20100028428A1 (en) 2010-02-04
BRPI0719693A2 (pt) 2013-12-24
WO2008068231A1 (en) 2008-06-12
PE20081350A1 (es) 2008-09-18
AR064149A1 (es) 2009-03-18
JP5894239B2 (ja) 2016-03-23

Similar Documents

Publication Publication Date Title
UA97813C2 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
EP1200090B1 (en) Pharmaceutical formulation comprising a beta-carboline and its use for treating sexual dysfunction
AU2021204135B2 (en) Dispersible compositions
KR101849808B1 (ko) 난용성 약물의 용해성 개선 제제
EA013686B1 (ru) Гидрохлорид 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
CA2167570C (en) Flavanolignan preparations with improved liberation and resorbability
KR101503559B1 (ko) 경구 분립상 항종양제
US20230390302A1 (en) Pharmaceutical formulation
CN109232293A (zh) 芬乐胺晶g型、制备方法和其组合物与用途
CN107693516B (zh) 一种地拉罗司药物组合物及其药物制剂、制备方法和用途
CN102048738A (zh) 含有环嘧耐平药用复合物的药物组合物制剂
EA042247B1 (ru) Диспергируемые композиции
CN102440959A (zh) 一种匹多莫德脂质体固体制剂
CN1672682A (zh) 含黄藤素微囊的制剂及其制备方法